Topics

BerGenBio Presents Updated Phase 2 NSCLC Clinical and Translational Data for Bemcentinib in Combination With KEYTRUDA

07:34 EST 8 Nov 2019 | FinanzNachrichten

- BerGenBio's proprietary Composite AXL Tumor-Immune Score predicts patients that have significantly prolonged clinical benefit - Primary endpoint of ORR in cohort A met, in predominantly PD-L1 lo...

Original Article: BerGenBio Presents Updated Phase 2 NSCLC Clinical and Translational Data for Bemcentinib in Combination With KEYTRUDA

NEXT ARTICLE

More From BioPortfolio on "BerGenBio Presents Updated Phase 2 NSCLC Clinical and Translational Data for Bemcentinib in Combination With KEYTRUDA"

Quick Search